This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-02 and is reviewed periodically as new material appears.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
== Chemistry == Nordazepam is similar to diazepam, except that the methyl group at the R1 position has been replaced with a hydrogen. Nordazepam can be synthesized with 2-amino-5-chlorobenzophenone and chloroacetyl chloride. Nordazepam itself can also be used in the synthesis of diazepam by methylating the R1 position using dimethyl sulfate.
Presumably, these genetic abnormalities lead to the activation of the NF-κB pathway and/or other cellular activation pathways which promote the survival, proliferation, and/or other malignant phenotypic traits in pDC and thereby cause BPDCN.
Sulfuric acid is a colorless oily liquid, and has a vapor pressure of <0.001 mmHg at 25 °C and 1 mmHg at 145.8 °C, and 98% sulfuric acid has a vapor pressure of <1 mmHg at 40 °C. In the solid state, sulfuric acid is a molecular solid that forms monoclinic crystals with nearly trigonal lattice parameters. The structure consists of layers parallel to the (010) plane, in which each molecule is connected by hydrogen bonds to two others. Hydrates H2SO4·nH2O are known for n = 1, 2, 3, 4, 6.5, and 8, although most intermediate hydrates are stable against disproportionation.
=== Charterism === In line with Seekings's latter point, some historians have assigned a central role to the rise of what was known by 1984 as Charterism: adherence to the Freedom Charter, the anti-apartheid political manifesto adopted at the 1955 Congress of the People (and subsequently banned by the apartheid state). After a period of dormancy inside the country while Black Consciousness ideology predominated, Charterism had been revived from around 1979. On some accounts, this revival was partly the result of the interest of young people, and COSAS, certainly, was fiercely Charterist. Although the UDF had not yet formally adopted the Freedom Charter, many of its affiliates and leaders, while usually identifying implicitly with the ANC, identified explicitly with the Charter; and the growth of the UDF contributed to the spread of Charterism. According to Raymond Suttner:A whole generation had grown up without access to literature about the Congress movement. This is not to say that the memory was wiped out, but there was a rupture, organisationally, in terms of symbols and also in the free and widespread diffusion of values. The UDF reconnected people to that tradition...Widespread subscription to the principles of the Freedom Charter, in turn, may have partly inspired the uprising, particularly insofar as the Freedom Charter provided a framework for "linking everyday grievances to aspirations for a new society" or, in other words, for the identification of "the intersection between localised grievances and the strategies and ideology of the ANC".
metabolite An intermediate or end product of metabolism, especially degradative metabolism (catabolism); or any substance produced by or taking part in a metabolic reaction. Metabolites include a huge variety of small molecules generated by cells from various pathways and having various functions, including as inputs to other pathways and reactions, as signaling molecules, and as stimulators, inhibitors, and cofactors of enzymes. Metabolites may result from the degradation and elimination of naturally occurring compounds as well as of synthetic compounds such as pharmaceuticals.
Sources: en.wikipedia.org
=== Ending manufacture === Citing health concerns, several manufacturing companies have ended or stated that they plan to end the sale of PFAS or products that contain them. These companies include W. L. Gore & Associates (the maker of Gore-Tex), Patagonia, REI, H&M, and 3M. An alternative for some companies may have been to move production to countries such as Thailand and India, where there is less regulation.
Chymopapain is one of the substracts used in chemonucleolysis (a type of percutaneous discectomy). This method was a new proposal to treat primary lumbar intervertebral disc disease using a nonsurgical method. As a matter of fact, the treatment consists on an injection of proteolytic enzymes to dissolve the herniated nucleus pulposus of the intervertebral discs. Purified chymopapain is the main component of the injection, composed basically of 20 mg in five millilitres. It is provided in vials containing 10.000 units of the lyophilized agent with 0.37 mg of disodium edetate, 3.5 mg of cysteine hydrochloride monohydrate and 1.0 mg of bisulfide. All of them work as stabilisers and activators. Sodium hydroxide is in charge of adjusting the PH of the solution. Then, the injection is rehydrated with 5 milliliters of sterile water. A surgeon injects the solution directly into the herniated disc on the spine to dissolve part of it and ease the pain. This process is under fluoroscopic control. Chymopapain is responsible for catalysis, both in vivo and in vitro, a rapid reduction in the viscosity and, as a consequence, the weight of the nucleus pulposus. In fact, it is a depolymerization of the chondromucoprotein and a decrease in the ability of a disk to imbibe fluid. The dose for a single intervertebral disc is 2 to 4 nanokatals, with a maximum dose per patient of 8 nanokatals. Chymopapain injections are normally given under local, rather than general, anaesthesia. This enzyme has been studied by universities departments around the world.
=== Detection frequency === The GC-O analysis is carried out by a panel of 6–12 assessors to count the number of participants who perceive an odour at each retention time. This frequency is then used to represent the relative importance of an odorant in the extract. It is also presumed to relate to the intensity of the odorant at the particular concentration, based on the assumption that individual detection thresholds are normally distributed. Two different kinds of data can be reported by this method depending on the data collected. First, if only frequency data is available, it is reported as the nasal impact frequency (NIF) or the peak height of the olfactometric signal. It is zero if no assessor senses the odour and added with one each time an assessor senses an odour. Second, if both frequency of detection and duration of odour are collected, the surface of NIF (SNIF) or the peak area corresponding to the product of frequency of detection (%) and duration of odour (s) can be interpreted. SNIF allows further interpretation of odour compounds other than just peak height. The detection frequency method benefits from its simplicity and lack of requirement for trained assessors, as the signal recorded is binary (presence/absence of odour). On the other hand, a drawback of this method is the limitation to the assumption of the relationship between frequency and perceived odour intensity. Odour-active compounds in food samples are often present at concentrations above their detection thresholds.
==== GBA gene ==== The GBA gene is associated with lysosome storage and autophagy. GBA encodes the enzyme glucocerebrosidase (GCase), necessary for breaking down glucosylceramide (GlcCer). Mutations in GBA can cause modifications in GCase protein structure, decreases in GCase activity and protein levels, and the accumulation of GlcCer in the cell. Approximately 5–15% of PD patients have mutations in the GBA gene. Mendelian genetics are not strictly observed in GBA mutations in PD. Both gain-of-function and loss-of-function GBA mutations are associated with increased risk of PD. GBA is one of a number of pleiotropic genes which have multiple effects in the body, that have been linked to PD risk. Mutations in GBA1 can cause either complete loss‐of‐function and the lysosomal disorder Gaucher's disease, or partial loss‐of‐function with an increased risk for PD. Mutations in EPG5 are implicated in a range of dysfunctions, from severe (Vici syndrome), to moderate (atypical parkinsonism) and mild (typical PD). Microdeletions at 22q11.2 have been variously linked to PD, schizophrenia, and DiGeorge syndrome.
=== Angiogenesis === Angiogenesis is an essential aspect of tumour development. In order for a tumour to grow and significantly increase in size, it must have a sufficient blood supply. If the tumour is unable to develop the blood supply it requires, cells within the tumour will begin to die and further growth will be halted. Angiogenic factors such as vascular endothelial growth factor (VEGF), stromal cell-derived factor 1 (SDF-1), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) are expressed by CAF to encourage the growth of new blood vessels. Some of these factors may also recruit cells that are vital to the angiogenic process, for instance SDF-1 attracts bone-marrow derived endothelial cells.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.